Your Health, We Care
Mirdametinib is a prescription medicine indicated for adult patients and children aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that cannot be completely removed by surgery.
The safety and efficacy of mirdametinib in children under 2 years of age have not been established.
Mirdametinib is a MEK inhibitor classified as targeted therapy, rather than conventional chemotherapy. Its mechanism of action involves blocking specific signaling pathways in the body that drive the growth of plexiform neurofibromas.
FDA，2025.11
A therapy for the treatment of adult and pediatric patients aged 2 years and older with NF1-PN.【more】
Article source：Lucius LaosRelease date：2026-10-21Recommended：5
Most common side effects of mirdametinib in adultsAccording to clinical trial data for mirdametinib, the most common adverse reactions in adult patients mainly include five aspects···【more】
Article source：Lucius LaosRelease date：2026-06-09Recommended：266
What is Mirdametinib?Mirdametinib is a prescription medicine specifically used to treat adults and pediatric patients aged 2 years and older who have neurofibromatosis type 1 (NF1)···【more】
Article source：Lucius LaosRelease date：2026-06-09Recommended：286
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
